Daily Cosmetic Research Analysis
Three impactful studies at the cosmetic–dermatology interface emerged today: (1) an optical biopsy cohort identified activated melanocytes and senescent collagen as predictors of melasma laser outcomes; (2) a systematic review supports ALA-PDT for superficial BCC and Bowen disease with superior cosmetic results but heterogeneous protocols; and (3) an enzymatic cascade produced glucoconjugated mycosporines as promising photostable, antioxidant UV filters.
Summary
Three impactful studies at the cosmetic–dermatology interface emerged today: (1) an optical biopsy cohort identified activated melanocytes and senescent collagen as predictors of melasma laser outcomes; (2) a systematic review supports ALA-PDT for superficial BCC and Bowen disease with superior cosmetic results but heterogeneous protocols; and (3) an enzymatic cascade produced glucoconjugated mycosporines as promising photostable, antioxidant UV filters.
Research Themes
- Predictive imaging biomarkers for cosmetic laser therapy
- Evidence synthesis for ALA-PDT with cosmetic outcomes
- Bio-based, enzymatically engineered UV filters with antioxidant activity
Selected Articles
1. Activated melanocytes and senescent collagen fibers predict laser-treated melasma outcomes: An optical biopsy-based prospective cohort study.
In a prospective cohort (n=15), cellular-resolution optical biopsy (CRFF-OCT) plus CADe revealed that pre-treatment activated melanocytes and senescent collagen patterns predict poorer response to picosecond alexandrite laser with a diffractive lens. Post-treatment, activated melanocytes/melanophages decreased and basement membrane integrity improved, while baseline MASI did not predict outcomes.
Impact: Introduces in vivo, cellular-resolution biomarkers to stratify melasma patients before cosmetic laser therapy, enabling personalized treatment and better counseling.
Clinical Implications: CRFF-OCT could be used to pre-screen melasma lesions: lesions with activated melanocytes and senescent collagen may require alternative or adjunctive approaches, closer follow-up, or modified laser parameters. Counseling should emphasize that baseline MASI alone is insufficient to predict response.
Key Findings
- MASI significantly decreased in 12/15 patients after PAL-DLA; 3 patients worsened.
- Activated melanocytes and senescent collagen patterns predicted less MASI improvement (p = 0.005).
- Basement membrane repair and reductions in activated melanocytes/melanophages were observed post-laser.
- Baseline MASI did not predict treatment outcomes.
Methodological Strengths
- In vivo cellular-resolution imaging (CRFF-OCT) with large image dataset (74,340 images) and automated CADe quantification.
- Prospective design comparing lesions and perilesions.
Limitations
- Small sample size (n=15) without a randomized comparator.
- Single-center study with limited follow-up; generalizability and durability of markers need validation.
- Findings specific to PAL with DLA; applicability to other devices unknown.
Future Directions: Multicenter validation studies with standardized imaging endpoints; integration of CRFF-OCT biomarkers into treatment algorithms; testing adjunctive therapies for lesions with senescent collagen signatures.
BACKGROUND: Melasma Area and Severity Index (MASI) score only assesses the pigmentation rather than photoaging. Picosecond alexandrite laser (PAL) with diffractive lens array (DLA) can improve photoaging and has been approved for melasma treatment. Prediction for post-laser outcome is limited. OBJECTIVE: To in vivo compare the photoaging milieu altered by a PAL with DLA in melasma lesions and adjacent perilesions, and to delineate the predictive factors for outcomes. METHODS: An optical biopsy with cellular resolution full-field optical coherence tomography (CRFF-OCT) was set up to evaluate the dynamic changes. Quantification was performed with the computer-aided detection (CADe) system. RESULTS: The mean MASI score decreased significantly (p < 0.001) in 12 of 15 patients but increased in the other three. An optical biopsy of 74,340 images showed the numbers of activated melanocytes and melanophages were significantly reduced post laser, and the basement membrane (BM) was repaired in melasma lesions, while basal lightening was noted in perilesions. The pre-treatment presence of activated melanocytes was associated with a high regional MASI score (p = 0.013), while the senescent collagen fibers and activated melanocyte patterns were associated with less MASI score improvement (p = 0.005). Senescent collagen fibers (p = 0.002) and baseline BM damage(p = 0.001) were strongly correlated to post-treatment melanophages. The baseline MASI score was not associated with activated melanocyte status or treatment outcomes. CONCLUSION: Optical biopsy using CRFF-OCT revealed that patterns of activated melanocytes and senescent collagen fibers can serve as predictive markers for post-laser treatment outcomes. The photoaging characteristics of melasma were improved through the reduction of activated melanocytes and the repair of the BM.
2. 5-aminolevulinic acid photodynamic therapy for the treatment of basal and squamous cell carcinoma: A systematic review.
Across 58 studies, ALA-PDT provides high clearance and superior cosmetic outcomes for superficial BCC and Bowen disease, with common adverse events of erythema, pain, and scaling. Response is lower in nodular BCC and SCC, and heterogeneity in protocols precludes firm consensus, highlighting the need for standardized RCTs.
Impact: Synthesizes a decade of evidence on ALA-PDT with explicit attention to cosmetic outcomes, guiding lesion selection and protocol optimization in dermatologic oncology.
Clinical Implications: Prefer ALA-PDT for superficial BCC and BD when cosmetic outcome is prioritized or surgery is contraindicated; avoid monotherapy for nodular BCC/SCC and counsel about higher recurrence risk in SCC. Standardization of ALA concentration, incubation, light source, and pretreatment is needed.
Key Findings
- High clearance and superior cosmetic outcomes for superficial BCC and Bowen disease with ALA-PDT.
- Lower response rates for nodular BCC and SCC; SCC shows higher recurrence rates.
- Significant protocol heterogeneity (ALA dose, light sources, incubation, pretreatment) precluded meta-analytic synthesis.
- Common adverse events: erythema, pain, scaling.
Methodological Strengths
- PRISMA-guided systematic review with GRADE-based quality assessment.
- Broad inclusion across study types and tumor entities (58 studies).
Limitations
- Marked heterogeneity in ALA-PDT protocols prevented standardized synthesis.
- Limited data and short follow-up for SCC; variable risk of bias across included studies.
Future Directions: Conduct head-to-head RCTs to standardize ALA dose, incubation times, pretreatment, and light sources, stratified by tumor subtype and thickness, with long-term cosmetic and recurrence endpoints.
BACKGROUND: 5-aminolevulinic acid photodynamic therapy (ALA-PDT) is used off-label in the US to treat basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and Bowen disease (BD). We performed a systematic review to assess the efficacy and safety of published ALA-PDT protocols for these conditions. METHODS: A PubMed search was conducted through August 8, 2024, to identify studies evaluating 10 % or 20 % ALA-PDT in BCC, SCC, and BD. Randomized controlled trials, observational studies, and case series with >5 patients were included. Quality assessment was performed using the Grading of Recommendations Assessment, Development, and Evaluation approach. RESULTS: Fifty-eight studies were included in the analysis (BCC, n = 40; SCC; n = 9, BD, n = 27). Considerable heterogeneity was observed in ALA concentration, light sources, incubation times, and pretreatment strategies, precluding a standardized synthesis of outcomes. ALA-PDT achieved high clearance rates for superficial BCC and BD, with superior cosmetic outcomes compared to surgery or cryosurgery. Studies of ALA-PDT for SCC were limited with short follow-up times. Nodular BCC and SCC lesions demonstrated lower response rates, particularly with ALA-PDT monotherapy. Recurrence rates varied widely and were highest in patients with SCC. The most frequent adverse events were erythema, pain, and scaling. CONCLUSIONS: This review provides a comprehensive summary of evidence-based ALA-PDT protocols for BCC, BD, and SCC, but published protocols are heterogeneous without a clear consensus. While ALA-PDT is effective, safe, and cosmetically favorable for less invasive tumors, protocol variability underscores the need for further randomized controlled trials to determine optimal treatment parameters.
3. Engineered mycosporine-based glucoconjugates by enzymatic cascade: Towards innovative ultraviolet filters and antioxidant compounds.
An enzymatic cascade using α-transglucosylase GS-D Δ1 (from L. animalis) efficiently glucosylated mycosporine-serinol (96% conversion), generating glucoconjugates with tunable linkages and chain lengths. The products retained strong photostability and antioxidant capacity, positioning them as sustainable candidates for next-generation UV filters.
Impact: Provides a green, modular route to engineer bio-based UV filters with antioxidant activity, addressing formulation instability and environmental concerns of current sunscreens.
Clinical Implications: If safety and efficacy are confirmed, these glucoconjugates could expand sunscreen actives with improved photostability and sustainability. Preclinical safety (phototoxicity, sensitization), dermal penetration, and formulation compatibility must precede clinical translation.
Key Findings
- α-Transglucosylase GS-D Δ1 glucosylated 96% of mycosporine-serinol, adding 1–3 glucosyl units.
- An enzymatic cascade yielded glucoconjugates with varied linkage specificity and chain length (including dextran-like chains).
- Glucosylated products showed photostability and antioxidant capacity comparable to free MSer(OH) and established antioxidants.
- Approach uses sucrose as a cheap donor, supporting scalable and sustainable production.
Methodological Strengths
- Novel biocatalytic route with high conversion efficiency and controllable glycosylation patterns.
- Direct assessment of photostability and antioxidant performance of products.
Limitations
- No in vivo safety/toxicity, photoprotection efficacy, or environmental fate data.
- Formulation performance (e.g., SPF, UVA-PF, stability in emulsions) not tested.
- Regulatory pathway for new UV filters remains uncertain.
Future Directions: Evaluate photoprotection (SPF/UVA-PF) in standardized in vitro and in vivo models, conduct toxicology and sensitization testing, and optimize dermal delivery within cosmetic formulations.
Mycosporine-serinol (MSer(OH)) is a small natural molecule with unique ultraviolet (UV) absorbing and antioxidant properties, but its hydrophilic and instable structure hampers its formulation for applications. Inspired by the fact that certain mycosporines are naturally glycosylated, this work assessed the development of an enzymatic route for the glucosylation of MSer(OH) using sucrose, a cheap and abundant resource. The newly characterized α-transglucosylase GS-D Δ1, from Ligilactobacillus animalis DSM 20602, stood out for its ability to glucosylate 96 % of MSer(OH) by grafting 1 to 3 glucosyl units. Then, an enzymatic cascade was established to produce various glucosylated-MSer(OH) differing in terms of linkage specificity and chain length. Their photostability and antioxidant capacities match those of free MSer(OH) or well-known antioxidants, making them potential competitors to commercial sunscreens. Notably, a MSer(OH)-based dextran chain over 10